Sanofi, E. coli

Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.”
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.
Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli.
Sanofi takes $250M hit after gamble on J&J E. coli vaccine ends in phase 3 failure
A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. | A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E.
Sanofi/J&J drop development of E. coli vaccine
French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine it it developing that will results in a significant impairment charge.
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. It will further negatively impact the full-year IFRS EPS reported in the Q4 2024 results by €0.15 from €4.59 previously to €4.44 now, according to the company's statement.
Sanofi Ends E.coli Vaccine Trial Amid Efficacy Concerns
Sanofi ( ($SNY) ) has provided an announcement. On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
The Financial Express11h
FDA gives nod to first rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the ...
Healio20h
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Banks on the Hook for Sanofi Buyout Face Agonizing Wait to Sell
Deal-starved banks lined up to make concessions to get a slice of Europe’s biggest buyout debt deal last year. They also put ...
policymed.com10d
Sanofi Sues HHS Over 340B Changes
Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources and ...